Arrowhead Pharmaceuticals Appoints New Director
Ticker: ARWR · Form: 8-K · Filed: Dec 18, 2024 · CIK: 879407
Sentiment: neutral
Topics: board-appointment, governance
Related Tickers: ARWR
TL;DR
Arrowhead Pharmaceuticals adds Dr. Christopher M. Marlett to its board.
AI Summary
Arrowhead Pharmaceuticals, Inc. announced on December 17, 2024, that its Board of Directors appointed Dr. Christopher M. Marlett as a new director, effective December 11, 2024. Dr. Marlett brings extensive experience in the life sciences industry, having previously served as CEO of Aptose Biosciences Inc. and as a founder of several biotechnology companies.
Why It Matters
The addition of a new director with significant industry experience could influence the company's strategic direction and governance.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment, which typically carries low risk.
Key Players & Entities
- Arrowhead Pharmaceuticals, Inc. (company) — Registrant
- Christopher M. Marlett (person) — Newly appointed director
- Aptose Biosciences Inc. (company) — Previous employer of new director
- December 17, 2024 (date) — Date of announcement
- December 11, 2024 (date) — Effective date of appointment
FAQ
Who is the new director appointed to Arrowhead Pharmaceuticals' Board?
Dr. Christopher M. Marlett was appointed as a new director.
When was the appointment of the new director effective?
The appointment was effective as of December 11, 2024.
What is Arrowhead Pharmaceuticals, Inc.'s state of incorporation?
Arrowhead Pharmaceuticals, Inc. is incorporated in Delaware.
What is Arrowhead Pharmaceuticals' business address?
Arrowhead Pharmaceuticals' business address is 177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105.
What was Dr. Christopher M. Marlett's previous role mentioned in the filing?
The filing mentions Dr. Marlett's previous role as CEO of Aptose Biosciences Inc.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-12-17 17:38:08
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ARWR The Nasdaq Global Select
Filing Documents
- arwr-20241211.htm (8-K) — 28KB
- 0001628280-24-051729.txt ( ) — 152KB
- arwr-20241211.xsd (EX-101.SCH) — 2KB
- arwr-20241211_lab.xml (EX-101.LAB) — 22KB
- arwr-20241211_pre.xml (EX-101.PRE) — 13KB
- arwr-20241211_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: December 17, 2024 ARROWHEAD PHARMACEUTICALS, INC. By: /s/ Kenneth Myszkowski Kenneth Myszkowski Chief Financial Officer